Medicare drug coverage
Gabapentin in Wisconsin: 2027 Part D coverage
97 of 97 Part D plans offered in Wisconsin (100%) list gabapentin on their 2027 formulary, the plan's list of covered drugs (up 1 point from 2026). 68% of those require prior authorization, step therapy, or a quantity limit. Plan counts include both Medicare Advantage plans with drug coverage (89 MA-PD) and stand-alone drug plans (8 PDP).
License: a US government work, in the public domain (Public Domain Mark 1.0).
For pharmacies and agencies: check a whole drug list against 2027 formularies.
Upload your patient list or your book of clients and Rivvi checks each drug against the CMS 2027 formulary files, plan by plan, so you see tier changes and new limits before the next refill or open enrollment. Free to start. HIPAA BAA included.
Every 2027 plan in Wisconsin
Each Part D plan offered in Wisconsin, with gabapentin's 2026 and 2027 tier and its 2027 limits. A tier is the cost level a plan puts a drug on; a lower tier usually costs less. Enter a ZIP to see only the plans offered in that county.
PA is prior authorization (the plan must approve it first), ST is step therapy (try another drug first), and QL is a quantity limit. D-SNP, C-SNP, and I-SNP are Special Needs Plans: for people with both Medicare and Medicaid, with certain chronic conditions, or who live in a nursing home or need that level of care. Plans are listed by plan ID.
| Plan | Plan ID | Type | 2026 tier | 2027 tier | 2027 PA / ST / QL | Change |
|---|---|---|---|---|---|---|
| UHC Complete Care WI-1 (PPO C-SNP) | H0294-002-000 | MA-PD (PPO C-SNP) | Tier 2 | Tier 2 | None | No change |
| AARP Medicare Advantage from UHC WI-0002 (PPO) | H0294-004-000 | MA-PD (PPO) | Tier 2 | Tier 2 | None | No change |
| AARP Medicare Advantage from UHC WI-6 (PPO) | H0294-015-000 | MA-PD (PPO) | Tier 2 | Tier 2 | None | No change |
| UHC Dual Advantage WI-V2 (PPO D-SNP) | H0294-027-000 | MA-PD (PPO D-SNP) | Tier 2 | Tier 2 | None | No change |
| Aetna Medicare Signature (HMO-POS) | H1206-002-000 | MA-PD (HMO-POS) | Tier 3 | Tier 3 | QL | No change |
| Community Care's Partnership Program (HMO D-SNP) | H2034-001-000 | MA-PD (HMO D-SNP) | Tier 1 | Tier 1 | None | No change |
| iCare Family Care Partnership (HMO D-SNP) | H2237-007-000 | MA-PD (HMO D-SNP) | Tier 2 | Tier 2 | QL | No change |
| Medica Prime Solution Thrift w/Rx (Cost) | H2450-007-000 | MA-PD (Cost) | Tier 2 | Tier 2 | QL | No change |
| Medica Prime Solution Focus w/Rx (Cost) | H2450-039-000 | MA-PD (Cost) | Tier 2 | Tier 2 | QL | No change |
| Humana Value Choice (PPO) | H3642-001-000 | MA-PD (PPO) | New plan ID | Tier 2 | QL | New plan ID in 2027 |
| UHC Dual Complete WI-Q1 (HMO-POS D-SNP) | H3794-002-000 | MA-PD (HMO-POS D-SNP) | Tier 2 | Tier 2 | None | No change |
| UHC Dual Advantage WI-V1 (HMO-POS D-SNP) | H3794-004-000 | MA-PD (HMO-POS D-SNP) | Tier 2 | Tier 2 | None | No change |
| UHC Dual Complete WI-YL (HMO-POS D-SNP) | H3794-010-000 | MA-PD (HMO-POS D-SNP) | New plan ID | Tier 2 | None | New plan ID in 2027 |
| UHC Dual Complete WI-S1 (HMO-POS D-SNP) | H3794-011-001 | MA-PD (HMO-POS D-SNP) | New plan ID | Tier 2 | None | New plan ID in 2027 |
| UHC Dual Complete WI-S1 (HMO-POS D-SNP) | H3794-011-002 | MA-PD (HMO-POS D-SNP) | New plan ID | Tier 2 | None | New plan ID in 2027 |
| UHC Dual Complete WI-S1 (HMO-POS D-SNP) | H3794-011-003 | MA-PD (HMO-POS D-SNP) | New plan ID | Tier 2 | None | New plan ID in 2027 |
| Anthem Medicare Advantage 3 (PPO) | H4036-008-000 | MA-PD (PPO) | Tier 2 | Tier 2 | QL | No change |
| Molina My Choice Partnership (HMO D-SNP) | H5209-005-001 | MA-PD (HMO D-SNP) | Tier 2 | Tier 2 | QL | No change |
| Molina My Choice Partnership (HMO D-SNP) | H5209-005-002 | MA-PD (HMO D-SNP) | Tier 2 | Tier 2 | QL | No change |
| Molina My Choice Dual Advantage (HMO D-SNP) | H5209-006-001 | MA-PD (HMO D-SNP) | Tier 2 | Tier 2 | QL | No change |
| Molina My Choice Dual Advantage (HMO D-SNP) | H5209-006-002 | MA-PD (HMO D-SNP) | Tier 2 | Tier 2 | QL | No change |
| Legacy Rx (HMO-POS) | H5211-004-000 | MA-PD (HMO-POS) | Tier 1 | Tier 1 | QL | No change |
| Esteem Rx (HMO) | H5211-012-000 | MA-PD (HMO) | Tier 1 | Tier 1 | QL | No change |
| Esteem Rx Silver (HMO-POS) | H5211-014-000 | MA-PD (HMO-POS) | New plan ID | Tier 1 | QL | New plan ID in 2027 |
| Esteem Rx Gold (HMO-POS) | H5211-015-000 | MA-PD (HMO-POS) | New plan ID | Tier 1 | QL | New plan ID in 2027 |
Data only, not plan advice. Confirm on Medicare.gov Plan Finder or 1-800-MEDICARE.
By dosage form
The 2027 formularies list gabapentin by dosage form. A plan can cover one form and leave off or restrict another, so each form is counted on its own.
| Dosage form | Plans that list it | Restricted (of listing) | Most common tier |
|---|---|---|---|
| Extended release oral tablet | 0 (0%) | none list it | none list it |
| Oral capsule | 97 (100%) | 66 (68%) | Tier 2 |
| Oral solution | 97 (100%) | 66 (68%) | Tier 3 |
| Oral tablet | 97 (100%) | 66 (68%) | Tier 2 |
Wisconsin compared with the nation
68% of the 97 Part D plans offered in Wisconsin leave gabapentin off the 2027 formulary or restrict it, against 78% nationally (10 points lower). Wisconsin ranks 42 of 51 states from most to least restrictive. A plan offered in several states counts in each.
2027 compared with 2026
| Measure | 2026 | 2027 | Change |
|---|---|---|---|
| Part D plans in the file | 100 | 97 | -3 |
| Plans that list it | 99 (99%) | 97 (100%) | +1 point |
| Prior authorization (of plans that list it) | 1 (1%) | 0 (0%) | -1 point |
| Step therapy (of plans that list it) | 0 (0%) | 0 (0%) | no change |
| Quantity limit (of plans that list it) | 67 (68%) | 66 (68%) | no change |
| Any of the three (of plans that list it) | 67 (68%) | 66 (68%) | no change |
| Not listed or restricted (of all plans) | 68 (68%) | 66 (68%) | no change |
Formulary tier
| Tier | 2026 plans | 2027 plans |
|---|---|---|
| Tier 1 | 17 (17%) | 18 (19%) |
| Tier 2 | 73 (74%) | 72 (74%) |
| Tier 3 | 9 (9%) | 7 (7%) |
Plan by plan, 2026 to 2027
| Plan by plan | Plans |
|---|---|
| Same plan ID in both years | 85 |
| Listed it in 2026, not in 2027 | 0 (0%) |
| Listed it in 2027, not in 2026 | 0 (0%) |
| Moved it to a higher tier | 1 (1%) |
| Moved it to a lower tier | 3 (4%) |
| Added prior authorization | 0 (0%) |
| Added step therapy | 0 (0%) |
| Added a quantity limit | 0 (0%) |
| Added at least one of the three | 0 (0%) |
| Removed at least one of the three | 1 (1%) |
| Plan IDs new in 2027 | 12 |
| 2026 plan IDs not in the 2027 file | 15 |
The CMS summary has no count of tier moves down, so "Moved it to a lower tier" is counted from the plan rows on this page: plans with the same plan ID in both years that list gabapentin both years.
Gabapentin in other states
- Alabama86% restrict or leave off, no changeAL
- Alaska78% restrict or leave off, no changeAK
- Arizona81% restrict or leave off, +2 pointsAZ
- Arkansas84% restrict or leave off, +2 pointsAR
- California61% restrict or leave off, -3 pointsCA
- Colorado69% restrict or leave off, +8 pointsCO
- Connecticut83% restrict or leave off, +4 pointsCT
- Delaware79% restrict or leave off, no changeDE
- District of Columbia52% restrict or leave off, -8 pointsDC
- Florida90% restrict or leave off, +2 pointsFL
- Georgia81% restrict or leave off, -1 pointGA
- Hawaii72% restrict or leave off, +3 pointsHI
- Idaho64% restrict or leave off, no changeID
- Illinois84% restrict or leave off, -1 pointIL
- Indiana84% restrict or leave off, +4 pointsIN
- Iowa80% restrict or leave off, -2 pointsIA
- Kansas82% restrict or leave off, +4 pointsKS
- Kentucky81% restrict or leave off, -1 pointKY
- Louisiana82% restrict or leave off, -2 pointsLA
- Maine77% restrict or leave off, +3 pointsME
- Maryland67% restrict or leave off, +2 pointsMD
- Massachusetts63% restrict or leave off, +3 pointsMA
- Michigan64% restrict or leave off, no changeMI
- Minnesota86% restrict or leave off, no changeMN
- Mississippi82% restrict or leave off, -4 pointsMS
- Missouri83% restrict or leave off, +3 pointsMO
- Montana85% restrict or leave off, +7 pointsMT
- Nebraska82% restrict or leave off, -2 pointsNE
- Nevada73% restrict or leave off, -6 pointsNV
- New Hampshire72% restrict or leave off, +8 pointsNH
- New Jersey84% restrict or leave off, +3 pointsNJ
- New Mexico51% restrict or leave off, -7 pointsNM
- New York70% restrict or leave off, no changeNY
- North Carolina84% restrict or leave off, +4 pointsNC
- North Dakota77% restrict or leave off, -2 pointsND
- Ohio82% restrict or leave off, +2 pointsOH
- Oklahoma75% restrict or leave off, -5 pointsOK
- Oregon82% restrict or leave off, +12 pointsOR
- Pennsylvania89% restrict or leave off, +1 pointPA
- Rhode Island62% restrict or leave off, +1 pointRI
- South Carolina87% restrict or leave off, no changeSC
- South Dakota87% restrict or leave off, no changeSD
- Tennessee84% restrict or leave off, -2 pointsTN
- Texas80% restrict or leave off, +2 pointsTX
- Utah72% restrict or leave off, -2 pointsUT
- Vermont86% restrict or leave off, +1 pointVT
- Virginia70% restrict or leave off, +3 pointsVA
- Washington63% restrict or leave off, +7 pointsWA
- West Virginia84% restrict or leave off, -4 pointsWV
- Wyoming85% restrict or leave off, +17 pointsWY
About this data
A plan here is one Part D plan as the CMS formulary files list it: contract, plan, and segment. That covers Medicare Advantage plans with drug coverage and stand-alone drug plans. A plan lists a drug when its formulary has a row for any RxNorm product of that name. When it has several, the row with the lowest tier is the one counted, and restricted means that row has prior authorization, step therapy, or a quantity limit.
A plan with no row for the drug counts as not listing it. That can be a product the file codes another way, so read a low count as a lookup result, not a coverage decision. A state counts every plan the CMS landscape file offers there. Parent organizations are named as CMS names them. The drug list is the top 200 by total Part D spending.
Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page
Source: CMS 2026 Part D formulary file (basic drugs and plan information), as of September 30, 2026. Publisher page
Source: CMS CY2027 landscape file (states and parent organizations), as of September 30, 2026. Publisher page
Source: CMS CY2026 landscape file, as of September 25, 2025. Publisher page
Source: CMS Medicare Part D Spending by Drug, 2024 data, as of June 25, 2026. Publisher page
Source: US Census Bureau 2020 ZCTA to county relationship file (ZIP lookup), as of December 9, 2021. Publisher page